Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rivaroxaban plus aspirin versus aspirin alone for endothelial function in peripheral artery disease
2019-003679-20Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban and aspirin in arteriosclerosis obliterans (2 arms), sponsored by Radboudumc. Primary endpoints: Dichotomized carotid artery reactivity after 3 months and Change in proportion of patients with carotid artery reactivity constriction. Started Mar 2021; status: completed.
02
Drugs
rivaroxabanaspirin
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2019-003679-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003679-20.